Apixaban is an oral factor Xa inhibitor that is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. It is also indicated for the treatment, prophylaxis, or the reduction in the risk of recurrence of deep vein thrombosis (DVT) or pulmonary embolism (PE). Apixban does not need to be monitored routinely, however, exceptions may include determination of failure of therapy vs. poor compliance, or potential dose adjustment required for renal or hepatic dysfunction.
Follow current CLSI guidelines for obtaining platelet-poor plasma.
Reported (Analytical Time)
The CPT codes provided are based on AMA guidelines and are for informational purposes only.
CPT coding is the sole responsibility of the billing party.
Please direct any questions regarding coding to the payer being billed.
Methodology: Chromogenic Transport Temperature: Frozen Reject Criteria: Clotted; hemolysis; icteric; grossly lipemic ** This test is not available for New York patient testing **